“The first thing they see is the loose skin on their abdomen," says R. Brannon Claytor, a Bryn Mawr, Pa.-based plastic ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales ...

Read a preview of Eli Lilly below and check back for more analysis soon. Investors already know what to expect when Eli Lilly ...